THE WELCH COMPANY
440 Davis Court #1602
San Francisco, CA 94111-2496
415 781 5700
rod@welchco.com
S U M M A R Y
DIARY: May 19, 2014 08:00 AM Monday;
Rod Welch
VA meeting Atorvastatin and Ezetimibe manage cholesterol Doctor Alba SF Medical Center.
1...Summary/Objective
2...Lab Electrolytes Cross Check Potassium T Bili Doctor Egan Request
3...Potassium T Bili Lab Cross Check Electrolytes Request Doctor Egan
4...VA Success Managing Cholesterol for Regression Atherosclerosis
5...Hyperlipidemia Cholesterol Controlled Exercise Diet Medication
6...Cholesterol Managed Clinical Trial Exercise Diet Medication
7...Clinical Trial Considered Lower Cholesterol Without Statin Drugs
8...Physical Activity Hike 300 Miles Per Month Prescription Lower CVD Risk
9...Weight Lowest 30 Years Prescribed Low Carb Diet and Physical Activity
10...Prescribed Care Implemented Rigorously through Doctor Patient Collaboration
...............Mileage 2014 Miles Minutes
11...HDL 67 Increased with Sufficcient Exercise Training
12...Orange Juice Clinical Trial Increases 21% with Sufficient Quantity
13...Atherosclerosis Regresses Rapidly With Elevated HDL and EPCs
14...Atorvastatin Ezetimibe Reduce Side Effects by Reducing Dose
15...Side Effects Reduced by Reducing Treatment with Regression Atherosclerosis
16...Regression Atherosclerosis Lowers CVD Risk Reduce Treatment Reduce Side Effects
17...Feet Pain Metatarsalgia Podiatry Referral Regression Atherosclerosis
18...Podiatry Resolve Metatarsalgia Feet Pain Maintain Regression Atherosclerosis
19...Atherosclerosis Podiatry Resolve Metatarsalgia Feet Pain Side Effects Physical Activity
20...CT Test Response Treatment Favorable Results Reduce Treatment Side Effects
21...Medical Chart Progress Notes Meeting 140519 VA SF Medical Center
..............
Click here to comment!
CONTACTS
SUBJECTS
VA Prescribe Atorvastatin 10 MG Trial 4 Weeks Evaluate Side Effects In 48
6003 -
6003 - ..
6004 - Summary/Objective
6005 -
600501 - Follow up ref SDS 81 0000. ref SDS 70 0000.
600502 -
600503 - Productive meeting with VA team; Doctor Alba ordered additional lab to
600504 - check Chem Profile on elevated potassium that may cause electrical
600505 - problems for the heart, noted by Doctor Egan in Cardiology at VA
600506 - Clinic in Martinez. Potassium and other electrolytes were reported
600507 - high in Labcorp test, but are needed in VA system for efficient case
600508 - management. ref SDS 0 HY6O VA has done excellent work with plan of
600509 - care combining medication and physical activity to maintain favorable
600510 - lipid labs. ref SDS 0 X59G Physical activity with endurance exercise
600511 - hiking 300+ miles per month increased HDL 67 from 30, when CABG +4
600512 - surgery was performed 5 years ago in 2009. Equally, EPCs are likely
600513 - elevated, which causes regression of atherosclerosis, and which in
600514 - turn lowers CVD risk. ref SDS 0 T64J Orange juice was also increased
600515 - in line with studies showing positive effects increasing HDL.
600516 - ref SDS 0 4Z8I Coronary CTA with calcium score provides standard of
600517 - care testing response to treatment reducing atherosclerosis plaques to
600518 - evaluate level of care managing CVD risk. ref SDS 0 WS4L The medical
600519 - team worries patient anatomy changes from CABG surgery in 2009, makes
600520 - testing difficult with coronary CTA. ref SDS 0 J83H Research
600521 - indicates CTA radiology modalities are standard of care for testing
600522 - response to treatment after CABG surgery. ref SDS 0 OF7N Patient
600523 - history of elevated atherosclerosis was cited during the meeting.
600524 - There was concern testing severity of atherosclerosis after 5 years of
600525 - treatment will not add value to adjust treatment regardless of
600526 - results. ref SDS 0 M16K Reviewed standard of care for evidenced based
600527 - medical practice requires testing to measure severity of medical
600528 - problems that guides treatment. Coronary CTA with calcium score
600529 - yields results in time to make effective changes, ref SDS 0 6W3M
600530 - Patients need timely testing to avoid tragic outcomes illustrated by
600531 - Tim Russert case, where results came too late for survival.
600532 - ref SDS 0 NB7N Doctor Alba noted favorable labs indicate current
600533 - treatment is effective, so why test for regression of atherosclerosis?
600534 - ref SDS 0 467K Reviewed rising side effects of prescribed care.
600535 - ref SDS 0 PC8K The doctor referred urination side effects to Primary
600536 - Care for possible prostate issues arising from aging process.
600537 - ref SDS 0 EK4F Doctor Alba will add T Bili to make-up electrolytes
600538 - lab in order to evaluate rising peripheral neuropathy. ref SDS 0 P26G
600539 - The doctor will investigate referral to podiatry for relief of side
600540 - effects hiking 300 miles per month in order to maintain level of care
600541 - required for regression of atherosclerosis. ref SDS 0 YM5N Considered
600542 - reducing treatment to lower side effects. Since current care has been
600543 - effective there is reluctance to reduce treatment without evidence
600544 - atherosclerosis plaques have regressed that lower CVD risk. The
600545 - doctor advised that minor side effects must be tolerated in order to
600546 - benefit from lowering risks of atherosclerosis. Doctor Alba will
600547 - discuss with the VA team using coronary CTA with calcium score to test
600548 - for regression of atherosclerosis that will provide evidence that
600549 - supports reducing debilitating side effects by reducing treatment.
600550 - ref SDS 0 635O
600552 - ..
600553 - [On 140520 0732 letter to VA Medical Center in San
600554 - Francisco cites discussion on sore feet side effects of
600555 - hiking to lower CVD risk. ref SDS 97 UT5M
600557 - ..
600558 - [On 140520 0732 at 1017 VA lab Chem Profile shows
600559 - electrolytes generally improved - potassium (K) 5.2
600560 - declined from 5.6 on Labcorp test on 140508, and from 5.4
600561 - in VA lab on 140203 - additionally, glucose 98 declined
600562 - from 103, sodium 139 declined from 144, and T Bil 1.2
600563 - declined from 2.2. ref SDS 97 ZG5O
600565 - ..
600566 - [On 140529 0942 letter to VA requests progress ordering EPC
600567 - lab, and requests order for coronary CTA with calcium score
600568 - standard of care testing response to treatment for
600569 - regression of atherosclerosis. ref SDS A1 QG38
600571 - ..
600572 - [On 140612 1048 letter from Doctor Alba says VA refuses to
600573 - order EPC and CTA tests to evaluate regression of
600574 - atherosclerosis because CABG surgery on 091022, changed
600575 - anatomy which renders CTA test difficult, and since
600576 - customer has history of atherosclerosis the VA will not
600577 - test whether the problem has been resolved, declined,
600578 - unchanged or worsened, ref SDS A2 X45G, reflecting remarks
600579 - by Doctor Feingold as presented in Progress Notes for
600580 - meeting at VA on 140519 0800. ref SDS 0 OW49
600582 - ..
600583 - [On 140626 1652 letter notifies VA case studies show
600584 - failure to perform timely testing causes negative patient
600585 - outcomes. ref SDS A4 MY51 VA reference to patient having
600586 - vessel plaques 5 years ago, begs the question of testing to
600587 - determine how much plaque, and level of care required, if
600588 - any, to treat current condition. ref SDS A4 MZ33 Evidence
600589 - shows CTA common practice to evaluate atherosclerosis
600590 - post CABG surgery. ref SDS A4 MZ54
600592 - ..
600593 - [On 140929 1418 received letter from Doctor Alba to call VA
600594 - and schedule another meeting on managing lipids; called and
600595 - scheduled meeting with Doctor Rao, an attending physician,
600596 - on 141024 0830. ref SDS A8 8E5N
600598 - ..
600599 - [On 141022 1523 Doctor Rao called and changed the time of
600600 - the meeting from 0830 to 0900 on 141024. ref SDS B0 IF5M
600601 -
600602 -
600604 - ..
6007 -
6008 -
6009 - Background
6010 -
6011 -
601101 - Lab on 131015, showing cholesterol remained high, 131015 0724,
601102 - ref SDS 56 BE6O, conflict with increased exercise and weight loss,
601103 - discussed in the letter to the medical team yesterday on 131016 1632.
601104 - ref SDS 57 IW57
601106 - ..
601107 - On 131017 1000 VA medical chart Progress Notes assessment report
601108 - patient status CAD stable, asymptomatic. hyperlipidemia not
601109 - controlled. ref SDS 58 T24N
601111 - ..
601112 - On 131017 1000 Doctor Egan proposed referring patient for clinical
601113 - trial to reduce cholesterol with new "targeted" drugs. ref SDS 58 179N
601115 - ..
601116 - On 131017 1000 VA medical chart Progress Notes assessment report
601117 - patient status hyperlipidemia not controlled, ref SDS 58 PSXT; Doctor
601118 - Egan makes referral to SF VA Medical Center for consult on
601119 - participation clinical trials, ref SDS 58 EU9F, with experimental
601120 - agents such as AMGEN 145 and REGN 727 to resolve multiple statin
601121 - intolerance. ref SDS 58 CN4H
601123 - ..
601124 - On 131103 received letter from VA SF Medical Center scheduling meeting
601125 - on 131121 1000, to consider clinical trial for lowering cholesterol.
601126 - ref SDS 60 YT4N
601128 - ..
601129 - On 131112 New York Times published several articles reporting that the
601130 - day before on 131113, American Heart Association published new
601131 - guidelines for treating CAD patients that expand use of statin
601132 - medication regardless of cholesterol levels, ref SDS 61 0001, and
601133 - further raise the LDL 70 to LDL 190, as a target for cardiovascular
601134 - risk. ref SDS 61 CW6H
601136 - ..
601137 - On 131114 New York Times published several articles reporting that the
601138 - day before on 131113, American Heart Association published new
601139 - guidelines for treating CAD patients. ref SDS 62 SH6G
601141 - ..
601142 - On 131121 1604 meeting with Doctor Alba at San Francisco Medical
601143 - Center - prescribed Atorvastatin 20 mg 4-week trial and evaluate
601144 - adding Zetia 10 mg, schedule follow up on 131219 0930. ref SDS 63 6H6K
601146 - ..
601147 - On 131121 1604 in another record later today, VA prescription RX #
601148 - 5674471 for Atorvastatin 20 mg has been ordered. ref SDS 65 GH5M
601150 - ..
601151 - On 131125 0005 letter from Karen reports VA work plan to take statin
601152 - drug low dose Atorvastatin 10 mg for 4 weeks, then add Zetia 10 mg in
601153 - clinical trial for lowering cholesterol. ref SDS 67 V154
601155 - ..
601156 - On 131125 0005 research seems to indicate this clinical trial of low
601157 - dose Atorvastatin 10 mg with Zetia 10 mg has lowered cholesterol LDL
601158 - 70.
601160 - ..
601161 - On 131205 1448 received new prescription for Atorvastatin 20 mg,
601162 - ordered by Doctor Alba today for 4-week trial to assess side effects
601163 - for adding 2nd drug, Zetia 10 mg to lower LDL 249. ref SDS 68 GH5M
601165 - ..
601166 - On 131216 0028 letter to Doctor Alba submit agenda for meeting at VA
601167 - SFMC on 131219. ref SDS 69 HY6O
601169 - ..
601170 - On 131219 0930 meeting Doctor Alba at San Francisco VA Medical Center
601171 - ordered Ezetimibe 10 mg prescription for adding to Atorvastatin, and
601172 - ordered blood test to evaluate changes in lipid profile. 131219 0930,
601173 - ref SDS 70 NJ6G
601175 - ..
601176 - On 131230 1450, received Ezetimibe in US mail, ref SDS 71 5N3O,
601177 - ordered by Doctor Alba on 131219, 131219 0930, ref SDS 70 6H6K; begin
601178 - trial to manage cholesterol with Atorvastatin 10 mg and Ezetimibe 10
601179 - mg, planned during meeting at VA on 131121 0930. ref SDS 63 6H6K
601181 - ..
601182 - On 140114 0845 letter to Diana request Progress Notes meeting 131219,
601183 - ref SDS 72 HY6O, and ask about expanding scope pending lab to include
601184 - LDL-P. ref SDS 72 2140
601186 - ..
601187 - On 140115 1842 letter Diana will look for Progress Notes meeting
601188 - 131219, ref SDS 73 HY6O; investigating prospects for ordering lab test
601189 - LDL-P, ref SDS 73 CE80; VA claims patient cholesterol and LDL are above
601190 - target. ref SDS 73 CE91 VA further claims testing LDL-P not effective
601191 - in this case because LDL-C is not optimal. ref SDS 73 FF4H
601193 - ..
601194 - On 140116 0814 letter thanks Doctor Alba for investigating to find
601195 - Progress Notes for meeting at VA on 131219. ref SDS 74 HY6O Cite
601196 - research indicating patient with discordant LDL-C high and LDL-P low,
601197 - shown in patient lab on 131015, constitutes least risk for
601198 - arteriolosclerosis disorder, CVD, myocardial infarction. ref SDS 74 735Y
601200 - ..
601201 - On 140128 1327 letter asks again about Progress Notes meeting 131219,
601202 - ref SDS 75 HY6O; report hiking 11 miles per day continued, weight hit
601203 - 165, ref SDS 75 TZ8U; ask where to get lab at VA Martinez, in San
601204 - Francisco, or at UCSF. ref SDS 75 TZ96 No side effects from
601205 - Atorvastatin and Ezetimibe. ref SDS 75 TZ99
601207 - ..
601208 - On 140131 0815 have not received instructions from VA on getting lab
601209 - to test LDL-P, so ordered test. ref SDS 76 OO5G lab blood draw at
601210 - Labcorp in Walnut Creek on Ygnacio Valley Road. ref SDS 76 NT6T
601212 - ..
601213 - On 140201 1159 obtained blood draw for Lipid NMR test at Labcorp on
601214 - Health Testing Centers order # 27716, ref SDS 77 KQ4L, showing
601215 - "concordance" LDL-P 861, LDL-C 81, HDL 61, TG 68, LDL (pattern A) size
601216 - = large buoyant protective. ref SDS 77 IM9N
601218 - ..
601219 - On 140203 1147 VA blood draw at Martinez clinic to cross check Labcorp
601220 - blood test. 140203 1147, ref SDS 78 KK9M, showing LDL-C 93, HDL 58, TG
601221 - 47, ref SDS 78 IM9N, indicating "concordance" LDL-P 626, LDL (pattern
601222 - A) size = large buoyant protective. ref SDS 78 QV5G
601224 - ..
601225 - On 140204 1236 letter from VA today, notifies that Progress Notes for
601226 - meeting on 131219, have been posted and are available for customer to
601227 - receive from ROI department. ref SDS 79 HY6O Cause for 6-weeks delay
601228 - issuing Progress Notes not clear in the record. ref SDS 79 V44F VA
601229 - Progress Notes for meeting on 131219, are comprehensive and helpful.
601230 - ref SDS 79 MR3G Progress Notes have many minor grammatical errors
601231 - likely due to limited time, ref SDS 79 MZ5H, VA does not support NMR
601232 - lipid tests to determine LDL-P and discordance with LDL-C; patient can
601233 - obtain test from another lab. ref SDS 79 CE80 VA letter today
601234 - maintains discordance with low LDL-P and high LDL-C is "unhealthy" -
601235 - submits no evidence from medical literature supporting this
601236 - proposition, nor to address literature submitted to the VA stating
601237 - discordance is the healthiest condition for CVD patients. ref SDS 79
601238 - 6U4L VA concurs that lowering weight toward BMI standards aids
601239 - resolving hyperlipidemia. ref SDS 79 8N9H VA maintains lifestyle
601240 - through exercise and diet to control weight and hyperlipidemia require
601241 - support taking statin medications, e.g., Atorvastatin and Ezetimibe.
601242 - ref SDS 79 GT5F VA letter today says patient mis-reads literature on
601243 - discordance between LDL-P and LDL-C, and proposes discussions to
601244 - clarify this matter during meeting scheduled on 140213. ref SDS 79 HU5M
601245 - VA prefers patient get labs drawn at San Francisco VA Medical Center.
601246 - ref SDS 79 PT3M
601248 - ..
601249 - On 140211 0133 letter submits agenda to VA for meeting scheduled on
601250 - 140213. ref SDS 80 HY6O Progress Notes on 131219 received from VA on
601251 - 140204 1236. ref SDS 79 HY6O, stating LDL-P provides stronger
601252 - association with CVD risk, ref SDS 70 GO35, and VA letter saying
601253 - patient can support the team with NMR lab, reported on 140204 1236.
601254 - ref SDS 79 CE80, was implemented on February 1 using Labcorp. VA
601255 - request to have lab at San Francisco reported on 140204 1236.
601256 - ref SDS 79 PT3M, was received the day after lab was drawn at Martinez.
601257 - Will do VA labs in San Francisco for next cycle. ref SDS 80 TU68
601259 - ..
601260 - On 140211 0133 letter notifies VA consolidated patient history shows
601261 - strong alignment, ref SDS 80 TV31, between NMR test on 140201, and VA
601262 - lipid panel 2 days later on 140203. ref SDS 78 IM9N Low LDL-P 861
601263 - concordant with low LDL-C 81 in Labcorp NMR report on 140201. TG 47
601264 - and HDL 58 in VA lab 2 days later on 140203 1147, ref SDS 78 5C7M,
601265 - aligns with Labcorp results. ref SDS 80 TV3M Labcorp further shows
601266 - LDL size 21.3 is "pattern A", indicating large, buoyant LDL particles
601267 - "protect" against CVD. While research indicates discordance with
601268 - LDL-P low and LDL-C high is the healthiest cardiovascular condition
601269 - shown on 131125 0005, ref SDS 67 FI3G, and submitted to the VA in a
601270 - letter on 140116 0814, ref SDS 74 H29T; and previously cited in a
601271 - prior letter on 140114 0845, ref SDS 72 2140, patient healthy and very
601272 - grateful for outstanding care by entire VA team. ref SDS 80 TV3M
601274 - ..
601275 - On 140211 0133 letter notifies VA lab on 140203 improving prior lab on
601276 - 131015, ref SDS 80 TV40, resulted from Atorvastatin 40 mg - 4 weeks
601277 - beginning on 131121, shown in case study on 120101 0900, ref SDS 29
601278 - RN3F, then Atorvastatin 10 mg and Ezetimibe 10 mg beginning on 131230,
601279 - also in case study, ref SDS 29 6A6H, making total for 8 weeks
601280 - Atorvastatin 1850 mg, Ezetimibe 340 mg; as well, hiking 933 miles,
601281 - weight loss to 165, low-carb diet, chia seeds, orange juice, as
601282 - further set out in the record for the lab at the VA on 140203.
601283 - ref SDS 78 I17G
601285 - ..
601286 - On 140211 0133 letter notifies VA lab on 140203 shows potassium (K 5.4)
601287 - is elevated again, ref SDS 80 TV5F, and T Bilirubin 2.1 further
601288 - increased again, while Labcorp shows these are stable. ref SDS 78 ZG5O
601290 - ..
601291 - On 140213 0830 meeting at VA Medical Center in San Francisco
601292 - ref SDS 81 195I, good progress lowering risks of CVD based on
601293 - concordant low LDL-P 861 with low LDL-C 81. shown by lab NMR lipid
601294 - panel. ref SDS 81 TB6J Medical team excellent results collaborating
601295 - doctor/patient partnership. ref SDS 81 1L7M Atorvastatin 40 mg
601296 - started 131121, and then changed to Atorvastatin 10 mg with Ezetimibe
601297 - 10 mg started 131230. ref SDS 81 IE7F No side effects taking
601298 - medication. ref SDS 81 333L Discordance between LDL-P and LDL-C
601299 - discussed. ref SDS 81 WM8J Continue medication, diet, exercise and
601300 - weight loss protocols, and test lipid panel again in 3 months on
601301 - 140519 0800. ref SDS 81 8X5O
601303 - ..
601304 - On 140213 0830 meeting at VA Medical Center in San Francisco request
601305 - test for regression of atherosclerosis plaque using coronary CTA to
601306 - evaluate CVD risk which 5 years earlier required surgery in 2009.
601307 - ref SDS 81 JZ4O
601309 - ..
601310 - On 140213 0830 Progress Notes for meeting at VA Medical Center in San
601311 - Francisco have numerous errors, e.g., failing to report hiking 933
601312 - miles that lowered Triglycerides and raised HDL to reduce CVD risk
601313 - through regression of atherosclerosis. ref SDS 81 O55H VA
601314 - representation that LDL "still not at goal" conflicts with the record,
601315 - and fails to present the "goal" and the authority that supports it.
601316 - ref SDS 81 WF5J VA representation that total cholesterol and LDL-C
601317 - are above target conflicts with the most recent lab showing both labs
601318 - are below target. ref SDS 81 5I7H
601320 - ..
601321 - On 140213 0830 Progress Notes for meeting at VA Medical Center in San
601322 - Francisco state LDL-P has stronger association with cardiovascular
601323 - risk than LDL-C. ref SDS 81 S35H Patient LDL-P 861 with Labcorp test
601324 - on 140201, is "optimal" - 150 points lower target of 1000 for minimal
601325 - CVD risk, shown in consolidated lab on 140203. ref SDS 78 BE6O VA
601326 - representation that patient LDL-C is not at optimal levels conflicts
601327 - with VA record of lab tests on 140203 1147, ref SDS 78 BE6O, and is
601328 - otherwise not supported by reference to recognized authority.
601329 - ref SDS 81 S35H
601331 - ..
601332 - On 140213 0830 Progress Notes for meeting at VA Medical Center in San
601333 - Francisco Plan of care prescribes continue physical activity and low
601334 - fat/low cholesterol diet. ref SDS 81 E34O
601336 - ..
601337 - On 140226 1332 letter to VA transmits notes of meeting on 140213.
601338 - ref SDS 82 HY6O Report cold symptoms side effects taking Atorvastatin
601339 - with Ezetimibe. ref SDS 82 JY8K Request coronary CTA radiology test
601340 - regression atherosclerosis. ref SDS 82 JR99 Request Progress Notes
601341 - meeting on 140213. ref SDS 82 JY4M
601343 - ..
601344 - On 140303 1644 letter to VA reports recovery from symptoms of cold,
601345 - which may indicate this was not caused by prescribed medication side
601346 - effects taking Atorvastatin and Ezetimibe. ref SDS 83 HY6O Letter
601347 - requests Progress Notes for meeting a few weeks ago at Medical Center
601348 - in San Francisco, and because Release of Information (ROI) department
601349 - at the VA Clinic in Martinez has been delayed issuing patient medical
601350 - records. ref SDS 83 E788
601352 - ..
601353 - On 140305 1117 letter to VA follows up asking about work plan in
601354 - Progress Notes doing CT and other testing to evaluate regression of
601355 - atherosclerosis, ref SDS 84 WY3X, since CABG x4 surgery on 091022
601356 - 0700. ref SDS 15 PQWU
601358 - ..
601359 - On 140307 1509 letter notifies VA that Ezetimibe and Atorvastatin
601360 - prescription refill not delivered, and so treatment is paused pending
601361 - delivery. 140307 1509, ref SDS 85 5N3O
601363 - ..
601364 - On 140307 1509 at 1730 VA letter reports plans to investigate to
601365 - resolve delayed delivery of prescription refill for Atorvastatin and
601366 - Ezetimibe. ref SDS 85 MS9N
601368 - ..
601369 - On 140308 0956 another letter asking VA to investigate delayed
601370 - delivery medication refills. ref SDS 86 II91
601372 - ..
601373 - On 140310 0939 another letter to VA requests assistance again
601374 - resolving delayed delivery medication refills for Atorvastatin and
601375 - Ezetimibe. ref SDS 87 LS88 On 140310 0939 at 1121 VA letter responds
601376 - to letter sent at 0939, and asks if medication refills have been
601377 - delivered for Atorvastatin and Ezetimibe. ref SDS 87 VP4J At 1156
601378 - notified VA have not received medication. ref SDS 87 345R
601380 - ..
601381 - On 140311 1730 received prescription refill for Atorvastatin and
601382 - Ezetimibe, delivered by neighbor because mailman delivered to the
601383 - wrong mailbox; treatment resumed. ref SDS 88 YS4O At 1903 notified VA
601384 - medication refill was received, so treatment resumed. ref SDS 88 KF5I
601386 - ..
601387 - On 140312 1720 letter to VA Medical Center in San Francisco submits
601388 - comments on Progress Notes for meeting on 140213. ref SDS 89 5N3O
601389 - Recommend corrections to avoid propagating errors forward when current
601390 - Progress Notes are used to expedite making Progress Notes for the next
601391 - meeting scheduled on 140519. ref SDS 89 IL83
601393 - ..
601394 - On 140312 1720 letter to VA Medical Center in San Francisco submits
601395 - question on goals for HDL and TG to lower LDL-P that has the strongest
601396 - association with CVD risk, ref SDS 89 IL4M, cited in VA Progress Notes
601397 - on 131219, ref SDS 70 GO35, and restated in Progress Notes for meeting
601398 - on 140213 0830. ref SDS 81 S35H
601400 - ..
601401 - On 140312 1720 letter to VA Medical Center in San Francisco requests
601402 - guidance in Progress Notes on goals for diet and exercise that yielded
601403 - dramatic rise in HDL 21% and reduction of TG 60%, given that research
601404 - indicates Atorvastatin and Ezetimibe have been found to increase HDL
601405 - 5%-9%, and lower TG 30%-40% [...reported on 131125 0005. ref SDS 67
601406 - PU6I...] - see AHA article Circulation published 030428...
601408 - ..
601409 - On 140312 1720 letter to VA Medical Center in San Francisco requests
601410 - testing for regression of atherosclerosis that lowers CVD risk based
601411 - on labs showing elevated HDL in combination with low TG, ref SDS 89
601412 - PSXX, discussed during the meeting on 140213 0830, ref SDS 81 JZ4O,
601413 - citing research on 131125 0005. ref SDS 67 E13K.
601415 - ..
601416 - On 140430 0900 at 0400 letter to Doctor Egan Cardiology VA Clinic
601417 - Martinez agenda for meeting 0900, ref SDS 91 HY6O, report patient
601418 - history of lipid labs, ref SDS 91 PT53, may show discordance with
601419 - LDL-P low and LDL-C high, indicating low risk CVD. ref SDS 91 PT6N
601421 - ..
601422 - On 140430 0900 at 0400 letter to Doctor Egan Cardiology VA Clinic
601423 - Martinez agenda meeting at 0900 reported maintained training protocol
601424 - hiking 11 miles daily, along with low-carb diet training for hiking
601425 - Half Dome on 140917. Weight has reached 164, as shown in patient
601426 - history, but is most often about 170 after hiking. ref SDS 91 PU34
601428 - ..
601429 - On 140430 0900 at 0900 meeting Doctor Egan Cardiology VA Clinic
601430 - Martinez discussed CTA imaging tests to assess regression of
601431 - atherosclerosis plaque, ref SDS 91 2F6O, that required CABG +4 on
601432 - 091022 0700, ref SDS 15 PQWU, as considered previously with the VA
601433 - during the meeting in San Francisco on 140213 0830, ref SDS 81 JZ4O,
601434 - and cited in the letter on 140312 1720. ref SDS 89 PSXX Doctor Egan
601435 - seemed to indicate that patient history of CABG +4 surgery 5 years ago
601436 - on 091022, makes evaluating regression of atherosclerosis unnecessary
601437 - to adjust prescribed care of medication and extended exercise for the
601438 - purpose of saving and money, and reducing painful side effects.
601439 - ref SDS 91 OK7L
601441 - ..
601442 - On 140430 0900 meeting Doctor Egan Cardiology VA Clinic Martinez
601443 - reported hiking stresses left knee injured in a fall of 40' back in
601444 - 1973, causing degenerative arthritis. In past month or so, feet have
601445 - begun to hurt, so it remains a challenge to control CVD risk through
601446 - exercise. Glucosamine Chondroitin helps resolve some of this problem,
601447 - with the result that hiking this year is about 300 miles ahead of the
601448 - record hiking through the 1st 4 months of last year. ref SDS 91 PU37
601449 - Doctor Egan encouraged extended endurance hiking for lowering LDL
601450 - cholesterol and triglycerides and raising HDL that reduce CVD risk.
601451 - ref SDS 91 RI9N The doctor asked about resting heart rate,
601452 - ref SDS 91 297N, this has reduced to below 60, due to increased
601453 - endurance hiking, shown from patient history beginning on 140422,
601454 - shown in case study on 120101 0900. ref SDS 29 RQ6H
601456 - ..
601457 - On 140430 0900 meeting Doctor Egan Cardiology VA Clinic Martinez
601458 - reported slight and occasional dizziness when laying down and turning
601459 - my head. ref SDS 91 PU43 Overall health very good. CT study on
601460 - 130117 showed esophagus has finally returned to normal, without the
601461 - big bubble that was there for 5 years or so. Accordingly, VA has
601462 - provided outstanding health care. ref SDS 91 PU47
601464 - ..
601465 - On 140430 0900 letter from Doctor Egan, Cardiology Physician at
601466 - Martinez Clinic, notes medical team did not address elevated potassium
601467 - in labs, and again notifies that this condition represents exposure to
601468 - "electrical problems" with the heart. ref SDS 91 UV5I
601470 - ..
601471 - On 140505 0936 Doctor Egan notified that medical team at VA Medical
601472 - Center in San Francisco was advised of concerns on elevated potassium
601473 - (K) and Total Bilirubin, ref SDS 92 YV4L, shown in labs reported in
601474 - the record on 140203 1147. ref SDS 78 ZG5O
601476 - ..
601477 - On 140508 1133 lab for VA from Labcorp at John Muir Clinic shows
601478 - glucose, sodium at high end of range, and shows potassium and T bili
601479 - above range, ref SDS 93 WJ5H, indicating influence of extended
601480 - endurance hiking 22 miles the day before, and another 11 miles morning
601481 - of the blood draw, and possibly caused by statin and ezetimibe
601482 - treatment to lower LDL cholesterol, as discussed in Notes of the lab
601483 - on 140508 1133. ref SDS 93 G34G Lipid panel shows further improvement
601484 - with LDL-P 851 down 10 points and HDL 67 up 6 points from 4 months
601485 - earlier. ref SDS 93 BE6O Improved lipid history, ref SDS 93 W25L,
601486 - reveres prior history of worsening lipids occurring after significant
601487 - improvement, and is attributed to increased endurance hiking 300 miles
601488 - per month and adding orange juice at approximately 500 ml per day.
601489 - ref SDS 93 I17G
601491 - ..
601492 - On 140514 0950 lab at VA Medical Center in San Francisco to support
601493 - meeting with Doctor Alba on 140519. ref SDS 94 X45G Excellent lipid
601494 - lab, ref SDS 94 IM9N, aligns with Labcorp blood test using NMR
601495 - technology last week on 140508 1133. ref SDS 93 5C7M Reflects
601496 - increased hiking and weight control past 3.5 months, reported in case
601497 - study on 120101 0900, ref SDS 29 PYXR, and supported with low carb
601498 - diet (including orange juice) and low dose medication, reported on
601499 - 140513, in the same study. ref SDS 29 ZU5G Favorable results seemed
601500 - "too good to be true" and so the VA lab did a second test to
601501 - corroborate findings shown by (a) and (b) scores. ref SDS 94 5C7M
601503 - ..
601504 - On 140515 2043 letter to VA submits consolidated results of Labcorp
601505 - test on 140508 with VA test on 140514, noting continued favorable
601506 - lipid panel improves patient history past 3 years of worsening results
601507 - after significant improvement. ref SDS 95 1V6M
601509 - ..
601510 - On 140515 2043 letter to VA submits reports meeting with Doctor Egan
601511 - in Cardiology at Martinez Clinic on 140430. ref SDS 95 YM67 After the
601512 - meeting, the doctor wrote a letter noting again that potassium (K) was
601513 - elevated in lab on 140203, and cited risk of "electrical problems" for
601514 - CAD patients (see line 392120. ref SDS 91 UV5I
601516 - ..
601517 - On 140515 2043 letter to VA reports that on 140513, weight dropped to
601518 - 163, lowest in 30 years, after hiking another 1000 miles since prior
601519 - labs in February, ref SDS 95 YM82, see case study (see line 105253
601520 - shown on 120101 0900. ref SDS 29 PYXR
601522 - ..
601523 - On 140515 2043 letter to VA reports medication side effects slight
601524 - dizziness in past month when laying down and turning my head left or
601525 - right. There may also be increased urination the past month or so,
601526 - but this is hard to track. Seem to be getting up a lot during the
601527 - night, as occurred with Rosuvastatin, but could be imagination - not
601528 - sure yet. ref SDS 95 YM98
601530 - ..
601531 - On 140515 2043 letter to VA requests coronary CTA with calcium score
601532 - to evaluate regression of atherosclerosis. ref SDS 95 YM41 Further
601533 - requests EPC lab to assess favorable conditions along with elevated
601534 - HDL for regression of atherosclerosis. ref SDS 95 YM61
601536 - ..
601537 - On 140515 2043 letter to VA reports labs show excellent care at the VA
601538 - achieving favorable results lowering CVD risk for continuing cycles.
601539 - As noted initially, in past years, whenever HDL increased and
601540 - Triglycerides dropped, on the next test the numbers got worse, see
601541 - patient Lipid History Trend Analysis on 140508 (line 610726.
601542 - ref SDS 94 W25L Thanks to skill and persistence of the VA medical
601543 - team, this time the numbers improved. ref SDS 95 YM64
601545 - ..
601546 - On 140518 2120 letter submits agenda to Doctor Alba for meeting
601547 - tomorrow on 140519, at VA Medical Center in San Francisco. ref SDS 96
601548 - 1V6M Medication side effects of dizziness seems to have subsided.
601549 - ref SDS 96 DV50 Very dry mouth in the night past week, and frequency
601550 - of urination has further increased, indicating dehydration issue,
601551 - possibly associated with elevated bilirubin. ref SDS 96 DV56
601552 - Peripheral neuropathy has returned, possibly related to bilirubin.
601553 - Follows prior pattern with Rosuvastatin, but at this time the problem
601554 - is very minor, only a few occasions the past 2 weeks or so.
601555 - ref SDS 96 DV59
601556 -
601557 -
601558 -
601559 -
601561 - ..
6016 -
6017 -
6018 - Progress
6019 -
6020 -
602001 - Lab Electrolytes Cross Check Potassium T Bili Doctor Egan Request
602002 - Potassium T Bili Lab Cross Check Electrolytes Request Doctor Egan
602003 -
602004 - Follow up ref SDS 96 DV4M, ref SDS 95 YM7H.
602005 -
602006 - Doctor Alba advised there wasn't enough time to read the letter to the
602007 - VA on 140515, ref SDS 95 YM7H, reporting Doctor Egan's request in a
602008 - letter on 140430, for follow up lab to re-check electrolyte panel,
602009 - ref SDS 91 UV5I, with primary concern about elevated potassium that
602010 - can cause electrical problems with the heart. ref SDS 91 UV5Y As a
602011 - result of a hectic schedule preventing timely review of the record,
602012 - the doctor's letter yesterday on 140518, notified that the VA decided
602013 - not to do an electrolyte lab, ref SDS 96 RW7O, responding to patient
602014 - letter also yesterday on 140518, ref SDS 96 DV4M, asking again about
602015 - following up on Doctor Egan's request on 140430, for a Chem Profile
602016 - (electrolytes) lab. ref SDS 91 UV5Y
602017 -
602018 - [On 140929 1418 received letter from Doctor Alba to call VA
602019 - and schedule another meeting on managing lipids; called and
602020 - scheduled meeting with Doctor Rao, an attending physician,
602021 - on 141024 0830. ref SDS A8 8E5N
602023 - ..
602024 - [On 141022 1523 Doctor Rao called and changed the time of
602025 - the meeting from 0830 to 0900 on 141024. ref SDS B0 IF5M
602027 - ..
602028 - This morning during the meeting we reviewed the record presented in
602029 - the letter on 140515 2043. ref SDS 95 1V6M
602031 - ..
602032 - Doctor Alba was pleased that Labcorp included electrolytes in the
602033 - recent lab on 140508. She indicated Labcorp results appear skewed by
602034 - patient physical activity hiking 22 miles the day before and another
602035 - 11 miles in the morning before the blood draw, reported in the letter
602036 - to the VA on 140515 2043, ref SDS 95 YM79, possibly causing Labcorp
602037 - test for potassium (K) 5.6 to actually increase from 5.4 even farther
602038 - above the range of 4.8 in prior VA lab on 140203, ref SDS 93 ZG5O, and
602039 - which was the cause of Doctor Egan's concern in the letter on 140430.
602040 - Doctor Alba also indicated that case management is faster and easier
602041 - for comprehensive care when patient history can be accessed directly
602042 - on the VA computer system, rather than rely on results from outside
602043 - labs, like Labcorp.
602045 - ..
602046 - As a result, she wants the patient to avoid physical exercise, in
602047 - particular stand down on 11 mile daily hikes until after the next lab.
602048 - She will order a Chem Profile (electrolytes) lab to check skewed
602049 - results for glucose, sodium, potassium and T Bilirubin in the Labcorp
602050 - lab on 140508, as shown with results for VA lab on 140514, which for
602051 - some reason omitted the electrolytes (Chem Profile panel). ref SDS 94
602052 - KK9M
602054 - ..
602055 - [On 140520 0732 letter to Doctor Alba requesting notice
602056 - that order has been placed for follow up lab for
602057 - electrolytes at the VA Medical Center prior to driving into
602058 - San Francisco. ref SDS 97 YW4H
602060 - ..
602061 - [On 140520 0732 at 0812 letter from Doctor Alba notifying
602062 - that order for electrolytes lab will be issued OA 0845.
602063 - ref SDS 97 4V5H
602065 - ..
602066 - [On 140520 0732 at 1017 VA lab Chem Profile shows
602067 - electrolytes generally improved - potassium (K) 5.2
602068 - declined from 5.6 on Labcorp test on 140508, and from 5.4
602069 - in VA lab on 140203 - additionally, glucose 98 declined
602070 - from 103, sodium 139 declined from 144, and T Bil 1.2
602071 - declined from 2.2. ref SDS 97 ZG5O
602072 -
602073 -
602075 - ..
602076 - VA Success Managing Cholesterol for Regression Atherosclerosis
602077 - Hyperlipidemia Cholesterol Controlled Exercise Diet Medication
602078 - Cholesterol Managed Clinical Trial Exercise Diet Medication
602079 - Clinical Trial Considered Lower Cholesterol Without Statin Drugs
602080 -
602081 - Follow up ref SDS 81 HY6O, ref SDS 70 HY6O.
602082 -
602083 - Doctor Alba very pleased LDL-P 851 dropped well below the target of
602084 - 1000 for good cholesterol health, indicating effective lipid
602085 - management for cardiovascular health. Equally critical HDL 67
602086 - increased again, and together with triglycerides (TG) 58 yield TG/HDL
602087 - ratio 0.88 that enables rapid regression of atherosclerosis, shown in
602088 - the record consolidating Labcorp test on 140508 with VA lab yesterday
602089 - on 140514 0950. ref SDS 94 IM9N
602091 - ..
602092 - During the prior meeting on 140213 0830, reviewed Doctor Alba's report
602093 - that LDL-P has the strongest association with CVD risk. ref SDS 81
602094 - UV4O This was confirmed in VA Progress Notes for meeting on 140213.
602095 - ref SDS 81 S35H At that time on 140213, reviewed research with the
602096 - doctor indicating lowest risk for CVD is low LDL-P and high LDL-C,
602097 - and; concomitantly the highest risk is high LDL-P and low LDL-C.
602098 - ref SDS 81 UV4O Doctor Alba's Progress Notes for the prior meeting
602099 - mention reviewing this research, but do not present the actual
602100 - findings. ref SDS 81 I35L
602102 - ..
602103 - Today, the doctor further noted the VA lab on 140514, found LDL-C 87
602104 - remains well below VA published goal LDL-C <= 131. ref SDS 94 5C7M
602105 - LDL-C 87 is more than 50% lower than current AHA guidelines for LDL-C
602106 - < 190, reported on 131112 1422. ref SDS 61 HT87
602108 - ..
602109 - Doctor Alba appreciated attribution in the letter on 140515,
602110 - commending the VA medical team for maintaining excellent lipid labs
602111 - over 2 cycles, ref SDS 95 YM64, which has not previously occurred in
602112 - patient history the past 8 years, beginning in 2006, shown in the
602113 - record of Patient Lipid History on 140514. ref SDS 93 W25L
602114 -
602115 -
602117 - ..
602118 - Physical Activity Hike 300 Miles Per Month Prescription Lower CVD Risk
602119 - Weight Lowest 30 Years Prescribed Low Carb Diet and Physical Activity
602120 - Prescribed Care Implemented Rigorously through Doctor Patient Collaboration
602121 -
602122 - Doctor Alba commended dropping weight to 163, lowest in 30 years,
602123 - after hiking 2 laps (22 miles) on 140513, reported in case study of
602124 - patient history on 120101 0900, ref SDS 29 ZU5G She credited
602125 - compliance with low carb diet and continuing physical activity
602126 - prescribed in Progress Notes on 140213 0830, ref SDS 81 MQ5G, for
602127 - reducing weight from 200 last year to 165 or even 160, which she
602128 - presented during a prior meeting at the VA on 131219, 0930.
602129 - ref SDS 70 A56N
602131 - ..
602132 - Favorable patient outcome reflects effective doctor patient
602133 - partnership through strong communications, illustrated by the letter
602134 - submitted on 140515, requesting coronary CTA with calcium score to
602135 - test response to treatment for regression of atherosclerosis.
602136 - ref SDS 95 YM41 Effective doctor patient collaboration at the VA
602137 - aligns with standard of care for evidence based medical practice, set
602138 - out in a letter to UCSF and Kaiser on 090725 2017. ref SDS 11 T55T
602140 - ..
602141 - Prescribed treatment to continue physical activity was implemented
602142 - hiking 11 miles per day and averaging 300 miles per month shown in
602143 - patient history on daily medication, diet, vitals and exercise, listed
602144 - in case study on 120101 0900. ref SDS 29 QJ5I
602146 - ..
602147 - Mileage 2014 Miles Minutes
602148 -
602149 - 131103....Oct................. 373 5757 ...... ref SDS 29 6F9N
602150 - 131201....Nov................. 172 2899 ...... ref SDS 29 XRPV
602151 - 131229....Dec................. 234 3324 ...... ref SDS 29 XXQY
602152 - 140202....Jan................. 347 5393 ...... ref SDS 29 YWST
602153 - 140302....Feb................. 234 3681 ...... ref SDS 29 PYWS
602154 - 140330....Mar................. 207 3313 ...... ref SDS 29 RXPR
602155 - 140427....Apr................. 310 4402 ...... ref SDS 29 RXVV
602156 - 140601....May...projected..... 322 5338 ...... ref SDS 29 SXWV
602158 - ..
602159 - This level of endurance exercise aids weight control and lowers
602160 - triglycerides, shown in research on 131125, ref SDS 66 U44L, which was
602161 - submitted to the VA in the letter on 140515. ref SDS 95 YM82
602162 -
602163 - [...below on 140519 0800 Doctor Alba noted that elevated T
602164 - Bilirubin that may drive or compound peripheral neuropathy
602165 - side effects of statin drugs, can also be caused by
602166 - vigorous exercise prescribed for continuing physical
602167 - activity to lower CVD risk. ref SDS 0 U56J
602168 -
602170 - ..
602171 - HDL 67 Increased with Sufficcient Exercise Training
602172 - Orange Juice Clinical Trial Increases 21% with Sufficient Quantity
602173 -
602174 - The same study reviewed on 131125, noted: "It is now fairly well
602175 - recognized that endurance exercise training can increase plasma HDL
602176 - cholesterol levels, if the exercise training stimulus is sufficient.
602177 - Furthermore, several studies have suggested that HDL-raising effect of
602178 - endurance exercise training could be largely explained by the
602179 - concomitant loss of body mass or fat." ref SDS 66 6R7O
602181 - ..
602182 - Patient lipid history shows HDL increased from 30 to 67 following CABG
602183 - +4 cardiothroacic surgery on 091022, reported in case study on 140514
602184 - 0950. ref SDS 94 W25L
602186 - ..
602187 - Orange juice was also discussed during the meeting today, for
602188 - contributing to 30% rise from HDL 50 on 131015, to HDL 67 on 140514,
602189 - shown in patient history on lipid labs in the record on 140514 0950.
602190 - ref SDS 94 W25L Doctor Alba feels this correlates with the study
602191 - reviewed on 131125 0005, ref SDS 66 K34L, and submitted to the VA in
602192 - the letter on 140515 2043, ref SDS 95 YM5N, also presented in the
602193 - record reviewing favorable HDL lab results on 140514 0950. ref SDS 94
602194 - LO4J
602196 - ..
602197 - [...below on 140519 0800 VA Progress Notes report patient
602198 - increased intake of orange juice; needs to show quantity of
602199 - juice consumed in relation to rise in HDL aligns with
602200 - published studies reporting favorable correlation.
602201 - ref SDS 0 PB4I
602203 - ..
602204 - In this case, drinking orange juice 1 gallon (3786 ML) per week (541
602205 - ML/day) added to diet on 131125, based on study indicating HDL
602206 - increased 21% over 4 weeks with 750 ml per day (i.e., 1.4 gal per
602207 - week), ref SDS 67 R48K, as reported to VA in letter on 140114 0845.
602208 - ref SDS 72 218O Some research also indicates grape juice increases
602209 - HDL; however, no studies have quantified this effect. Patient
602210 - actually drinks combination of lemon juice, orange juice, and grape
602211 - juice in large quantities to hydrate after hiking 11 miles per day.
602213 - ..
602214 - HDL 67 increase from HDL 50 = 34% rise in 6 months from Dec 2013 - May
602215 - 2014, shown in patient history on 140514. ref SDS 94 W25L, represents
602216 - approximately 7% for each 4 week period. It may reflect drinking 541
602217 - ML of orange juice rather than 750 ML per day used in the study.
602218 - Raising HDL consistently 7% over 4 weeks for 6 months taking only 541
602219 - ML in this case, presents improved results compared to study results
602220 - finding 500 ML of orange juice for 4 weeks had no effect on HDL
602221 - levels. Improved results in this case may indicate orange juice at
602222 - 540 ML/day combined with hiking 11 miles per day, discussed below,
602223 - provides a direct path to improve lipid profiles toward avoiding and
602224 - regressing atherosclerosis plaque.
602225 -
602226 -
602228 - ..
602229 - Atherosclerosis Regresses Rapidly With Elevated HDL and EPCs
602230 -
602231 - Follow up ref SDS 81 JZ4O.
602232 -
602233 - Research on 131125, further found that elevated HDL cholesterol
602234 - produced in the liver, together with circulating endothelial
602235 - progenitor cells (EPCs) produced in the bone marrow, both driven by
602236 - extended endurance exercise (e.g., running, hiking, biking, swimming),
602237 - ref SDS 66 6O9M, are pathophysiological conditions for rapid
602238 - regression of atherosclerotic plaques, ref SDS 66 HG90, thus lowering
602239 - CVD risk.
602240 -
602241 - [On 140520 0732 letter next day to VA requests adding EPCs
602242 - to make-up lab, ref SDS 98 4U46, ordered by Doctor Alba for
602243 - adding electrolytes to check for elevated potassium, per
602244 - discussion today above. ref SDS 0 VO4F
602246 - ..
602247 - Coronary CTA with calcium score provides standard of care testing
602248 - response to treatment reducing atherosclerosis plaques to evaluate CVD
602249 - risk, presented in the letter to the VA on 140515 2043, ref SDS 95
602250 - YM41, following up discussion during the prior meeting on 140213 0830.
602251 - ref SDS 81 JZ4O
602252 -
602253 - [On 140529 0942 letter to VA requests progress ordering EPC
602254 - lab, and requests order for coronary CTA with calcium score
602255 - standard of care testing response to treatment for
602256 - regression of atherosclerosis. ref SDS A1 QG38
602258 - ..
602259 - Doctor Alba noted advantages of physical activity for lowering CVD
602260 - risk prescribed in Plan of Care for Progress Notes on 140213.
602261 - ref SDS 81 MQ5G The doctor left the examination room to consult with
602262 - Doctor Feingold, attending.
602263 -
602264 - [...below on 140519 0800 Progress Notes work plan do not
602265 - include continuing physical activity that has yielded
602266 - favorable results. ref SDS 0 OW76
602268 - ..
602269 - Doctor Alba and Doctor Feingold returned about 20 minutes later.
602270 - Doctor Feingold maintained that coronary CT angiography (CCTA) testing
602271 - with calcium score cannot be used with patient history of CABG +4
602272 - cardiothoracic surgery on 091022, ref SDS 15 PQWU, because patient
602273 - physiology was changed in a manner and to a degree that prevents
602274 - effective interpretation of radiology CT scan results. He spread his
602275 - fingers and slid both hands together signifying complexity of tangled
602276 - coronary blood vessels intertwined by surgery that overwhelms medical
602277 - analysis, suggesting finding plaques for CABG patients is like looking
602278 - for the proverbial "needle in a haystack."
602280 - ..
602281 - Controversy using CCTA radiology studies in clinical cardiology
602282 - practice to assess atherosclerosis was cited in discussions at an
602283 - international conference considering prospects for HDL to regress
602284 - plaque, reported last year On 131125. ref SDS 66 1E51
602286 - ..
602287 - [...below on 140519 0800 VA Progress Notes cite discussion
602288 - ordering coronary CTA with calcium score to test response
602289 - to treatment in order and sets out explanation that such
602290 - testing is not standard of care for patients who have had
602291 - CABG surgery because heart bypass surgery changes anatomy.
602292 - ref SDS 0 OW49
602294 - ..
602295 - [On 140529 0942 letter to VA requests progress ordering EPC
602296 - lab, and requests order for coronary CTA with calcium score
602297 - standard of care to test for response to treatment to
602298 - achieve regression of atherosclerosis. ref SDS A1 QG38
602300 - ..
602301 - [On 151019 0930 CCTA with calcium score performed;
602302 - meeting with doctor in Radiology Department reviewed
602303 - requirements for calcium score to evaluate response to
602304 - treatment recovering from atherosclorosis. ref SDS B5
602305 - GR4K At the end of the meeting, the doctor agreed to
602306 - perform calcium score for comprehensive CCTA test.
602307 - ref SDS B5 LQ5F However, analyst's report merely says
602308 - "All the bypass grafts are patent." ref SDS B5 JW8O
602310 - ..
602311 - [On 151019 0930 addendum received on 160113, and issued
602312 - by Doctor Priyanka Jha reports finding no evidence of
602313 - atherosclerosis plaque in active coronary circulatory
602314 - system, or words to that effect. ref SDS B5 QW5F
602316 - ..
602317 - [On 170412 1000 Doctor Simpson indicated that Doctor
602318 - Feingold is the resident expert on lipids. ref SDS B6 V35H
602320 - ..
602321 - In this case, elevated coronary plaques required treatment with
602322 - surgery 5 years ago on 091022. Subsequent treatment with elevated
602323 - endurance exercise the past 3 years, and increased further the past 6
602324 - months, shown above, ref SDS 0 T64J, may have yielded rapid regression
602325 - of atherosclerotic plaques. Standard of care evaluating response to
602326 - treatment for patients with history of CABG requires testing for
602327 - elevated EPCs and ordering coronary CTA with calcium score to test
602328 - for evidence of atherosclerotic plaques...
602329 -
602330 - 1. PubMed
602332 - ..
602333 - Cardiac CT angiography after coronary bypass surgery:
602334 - prevalence of incidental findings.
602335 -
602336 - http://www.ncbi.nlm.nih.gov/pubmed/17646469
602338 - ..
602339 - 2. Journal of American College of Cardiology...
602340 -
602341 - http://imaging.onlinejacc.org/article.aspx?articleID=1879181
602343 - ..
602344 - 3. Computed Tomography Imaging in 2012
602345 -
602346 - http://books.google.ca/books?id=ASu3TUDBNCcC&pg=PA85&lpg=PA85&dq=coronary+CTA+CABG&source=bl&ots=IPn9-8gHpB&sig=iJsUE_5KAdrUjXV2kAY-Z28Rt0M&hl=en&sa=X&ei=c6asU53uBYKryATT_YGwAQ&ved=0CE8Q6AEwCA#v=onepage&q=coronary%20CTA%20CABG&f=false
602347 -
602348 - ...and saying in part...
602350 - ..
602351 - "Coronary CTA is highly accurate for the assessment of
602352 - coronary artery bypass graft (CABG) stenosis, and its use
602353 - for this purpose is endorsed by current Appropriate Use
602354 - Criteria.
602356 - ..
602357 - 4. Journal of Cardiology Cases
602358 - Volume 5, Issue 2, April 2012, Pages e92?e95
602360 - ..
602361 - Regression of coronary plaque after coronary artery bypass graft
602362 -
602363 - http://www.sciencedirect.com/science/article/pii/S1878540912000035
602364 -
602365 - ...and saying in part...
602367 - ..
602368 - Three years after treatment, 64-MDCT showed mild stenosis
602369 - and a regression of plaque in the LMT. The mean density of
602370 - the plaque was 73.1 HU (intermediate plaque) [...before
602371 - CABG and 32.4 after CABG; plaque size reduced from 20.7 to
602372 - 4.26...]
602374 - ..
602375 - Doctor Feingold seemed to say that coronary CTA tests with calcium
602376 - score are unnecessary, when there is already evidence of
602377 - atherosclerotic plaques, based on patient history of CABG surgery in
602378 - this case CABG +4 performed 5 years ago on 091022. ref SDS 15 PQWU
602379 -
602380 - [On 140626 1652 case study showing coronary CTA common
602381 - medical practice evaluate response to treatment testing for
602382 - regression atherosclerosis after CABG heart bypass surgery.
602383 - ref SDS A5 MZ54
602385 - ..
602386 - [On 141024 0900 follow up examination Doctor Rao repeated
602387 - policy position that CCTA does not yield reliable results
602388 - testing response to treatment for patients who have
602389 - undergone CABG procedure, due to surgical changes in
602390 - anatomy. ref SDS B2 S54M
602392 - ..
602393 - The doctor further seemed to say that, since atherosclerotic plaque
602394 - was found in this case 5 years ago during angiogram radiology testing
602395 - on 091021 0716, ref SDS 14 7L43, and required surgery the next day,
602396 - evidence based medical practice can now only rely on favorable lipid
602397 - testing, shown in the labs on 140508 and 140514, ref SDS 94 W25L, to
602398 - conclude atherosclerosis has not worsened. He further seemed to say
602399 - that testing for atherosclerosis after 5 years of treatment, with
602400 - coronary CTA and calcium score will not add value to current diagnosis
602401 - nor aid prescription for treatment regardless of results.
602403 - ..
602404 - No authorities, studies, published articles, nor evidence of any kind
602405 - was cited to justify failing to test for response to treatment.
602407 - ..
602408 - [...below on 140519 0800 VA Progress Notes cite discussion
602409 - ordering coronary CTA with calcium score to test response
602410 - to treatment in order and sets out explanation that such
602411 - testing is not standard of care for patients who have had
602412 - CABG surgery because heart bypass surgery changes anatomy.
602413 - ref SDS 0 OW49
602415 - ..
602416 - [On 140529 0942 letter to VA requests progress ordering EPC
602417 - lab, and requests order for coronary CTA with calcium score
602418 - standard of care to test for response to treatment to
602419 - achieve regression of atherosclerosis. ref SDS A1 QG38
602421 - ..
602422 - [On 140612 1048 letter from Doctor Alba says VA refuses to
602423 - order EPC and CTA tests to evaluate regression of
602424 - atherosclerosis because CABG surgery on 091022, changed
602425 - anatomy which renders CTA test difficult, and since
602426 - customer has history of atherosclerosis the VA will test to
602427 - evaluate whether the problem has been resolved, declined,
602428 - unchanged or worsened, ref SDS A2 X45G, reflecting remarks
602429 - by Doctor Feingold as presented in Progress Notes for
602430 - meeting at VA on 140519 0800. ref SDS 0 OW49
602432 - ..
602433 - [On 141024 0900 follow up examination Doctor Rao repeated
602434 - policy position that CCTA does not yield reliable results
602435 - testing response to treatment for patients who have
602436 - undergone CABG procedure, due to surgical changes in
602437 - anatomy. ref SDS B2 S54M
602439 - ..
602440 - [On 151019 0930 CCTA with calcium score performed;
602441 - meeting with doctor in Radiology Department reviewed
602442 - requirements for calcium score to evaluate response to
602443 - treatment recovering from atherosclorosis. ref SDS B5
602444 - GR4K At the end of the meeting, the doctor agreed to
602445 - perform calcium score for comprehensive CCTA test.
602446 - ref SDS B5 LQ5F However, analyst's report merely says
602447 - "All the bypass grafts are patent." ref SDS B5 JW8O
602449 - ..
602450 - [On 151019 0930 addendum received on 160113, and issued
602451 - by Doctor Priyanka Jha reports finding no evidence of
602452 - atherosclerosis plaque in active coronary circulatory
602453 - system, or words to that effect. ref SDS B5 QW5F
602455 - ..
602456 - [On 170412 1000 Doctor Simpson indicated that Doctor
602457 - Feingold is the resident expert on lipids. ref SDS B6 V35H
602459 - ..
602460 - Discussed role of testing to not merely diagnose medical problems, but
602461 - also measure severity that guides treatment. Evidence based medical
602462 - practice requires testing for response to treatment. Coronary CTA
602463 - with calcium score yields results in time to make effective changes.
602464 - Standard of care increases or decreases treatments, based on favorable
602465 - or adverse test findings.
602467 - ..
602468 - [On 140626 1652 letter notifies VA of case studies showing
602469 - failure to perform timely testing causes negative patient
602470 - outcomes. ref SDS A4 MY51 VA reference to patient having
602471 - vessel plaques 5 years ago, begs the question of testing to
602472 - determine currently how much plaque, and level of care
602473 - required, if any, to treat current condition. ref SDS A4
602474 - MZ33 Evidence shows CTA common procedure to evaluate
602475 - current condition post CABG surgery. ref SDS A4 MZ54
602477 - ..
602478 - For example, Tim Russert, well known NBC television news broadcaster
602479 - died of heart attack despite LDL-C 68, indicating this common
602480 - methodology of determining low CVD risk, i.e., LDL-C < 70, is not
602481 - dispositive of atherosclerosis. As here, his doctor knew he had
602482 - plaques, but not how much. The patient finally had a coronary CTA
602483 - which yielded an atherosclerosis calcium score of 250 that should have
602484 - been 0; however, there was not enough time to adjust line of care, and
602485 - Mr Russert suffered the consequences. (see again research on 131125
602486 - line NZ0402. ref SDS 67 N73K
602488 - ..
602489 - Clearly, patients should be notified through timely test results
602490 - whether mere appearance of favorable indirect test results with lipid
602491 - labs, are contradicted by more direct testing of atherosclerosis with
602492 - coronary CTA, so that alternatives measures can be taken in time to be
602493 - effective.
602495 - ..
602496 - Doctor Feingold seemed to say that since the patient has already been
602497 - treated with available pharmacology at the VA for recovering from
602498 - atherosclerosis, nothing more can be done at the VA in the event of
602499 - adverse findings.
602500 -
602501 - [On 170412 1000 Doctor Simpson indicated that Doctor
602502 - Feingold is the resident expert on lipids. ref SDS B6 V35H
602504 - ..
602505 - We reviewed favorable clinical trials of new PCSK9 family of drugs
602506 - coming online, discussed previously with the VA reported in Progress
602507 - Notes for the meeting on 131219 0930. ref SDS 70 WF5J and ref SDS 70
602508 - E35N If the VA does not have time to provide available care with
602509 - promising results, the independent action can be taken.
602511 - ..
602512 - Doctor Alba asked that since prescribed care to maintain physical
602513 - exercise at high levels has produced highly favorable results for HDL
602514 - 67 and TG 58, shown in VA and Labcorp labs on 140514 0950, ref SDS 94
602515 - W25L, if a coronary CTA test showed favorable results, i.e., minimal
602516 - to no atherosclerosis plaque, even calcium score of 0, how would this
602517 - change prescribed care?
602518 -
602519 - [...below on 140519 0800 Doctor will discuss with
602520 - colleagues ordering coronary CTA with calcium score to test
602521 - for favorable results that support reducing prescribed care
602522 - with medication and extended endurance training, since this
602523 - would reduce difficult side effects. ref SDS 0 635O
602524 -
602525 -
602527 - ..
602528 - Atorvastatin Ezetimibe Reduce Side Effects by Reducing Dose
602529 - Side Effects Reduced by Reducing Treatment with Regression Atherosclerosis
602530 - Regression Atherosclerosis Lowers CVD Risk Reduce Treatment Reduce Side Effects
602531 -
602532 - Follow up ref SDS 81 A36K.
602533 -
602534 - Atorvastatin side effects are listed on 130603 0930. ref SDS 54 PC6O
602535 - Ezetimibe side effects are listed on 131125 0005. ref SDS 67 GD8G
602537 - ..
602538 - The letter to the VA on 140515, advised of slight dizziness over
602539 - several months taking Ezetimibe may have declined past few days.
602540 - ref SDS 95 YM98 Doctor Alba was pleased with the update report in the
602541 - letter yesterday that dizziness has entirely subsided, shown on 140518
602542 - 2120. ref SDS 96 DV50
602544 - ..
602545 - She explained that some side effects eventually go away, as the body
602546 - adjusts to new chemistry taking foreign drugs.
602548 - ..
602549 - Urination has increased, but this is hard to track. Seem to be
602550 - getting up a lot during the night, as occurred with Rosuvastatin, but
602551 - could be imagination - not sure yet, also reported on 140515.
602552 - ref SDS 95 YM98 The letter yesterday on 140518, further clarified
602553 - have had very dry mouth at night over the past week, and frequency of
602554 - urination has further increased, indicating dehydration issue.
602555 - ref SDS 96 DV56
602557 - ..
602558 - Doctor Alba advised increased urination at night could reflect
602559 - prostate issues that arise normally with aging, based on patient age
602560 - of 69. Recommends review with Primary Care.
602562 - ..
602563 - Peripheral neuropathy has begun to return, possibly related to
602564 - elevated bilirubin in the lab on 140514 0950. ref SDS 94 015M This
602565 - follows prior pattern with Rosuvastatin, but at this time the problem
602566 - is very minor, only a few occasions the past 2 weeks or so, reported
602567 - in the letter yesterday on 140518 2120. ref SDS 96 DV59 Background on
602568 - difficulties of elevated T bilirubin causing peripheral neuropathy
602569 - from taking statin drugs is reported in the record on 140514 0950.
602570 - ref SDS 94 G34G
602572 - ..
602573 - Doctor Alba related making a review of patient history that shows
602574 - elevated T bilirubin since 2009- prior to initiation of statin drugs.
602575 - She advised this indicates elevated T bilirubin may not be caused by
602576 - taking Atorvastatin.
602577 -
602578 - Collection DT T Bili Range Source
602579 - 05/08/2014 15:28 2.5 H...0.3 - 1.2.. ref SDS A7 WJ5H
602580 - 20/05/2014 10:20 1.2 ....0.3 - 1.2.. ref SDS 97 015M
602581 - 08/05/2014 11:49 1.3 H...0.0 - 1.2.. ref SDS 93 015M
602582 - 03/02/2014 09:52 2.1 H...0.3 - 1.2.. ref SDS 78 015M
602583 - 01/02/2014 12:28 1.6 H...0.0 - 1.2.. ref SDS 77 015M
602584 - 15/10/2013 08:25 1.7 H...0.3 - 1.2.. ref SDS 56 015M
602585 - 29/05/2013 08:18 1.3 H...0.3 - 1.2.. ref SDS 51 1Y9G
602586 - 28/02/2013 08:36 1.3 H...0.3 - 1.2.. ref SDS 48 6S4F
602587 - 31/08/2012 15:24 2.3 H...0.3 - 1.2.. ref SDS 35 NV9M
602588 - 09/05/2012 11:24 2.5 H...0.3 - 1.2.. ref SDS 33 O46K
602589 - 09/02/2012 11:18 1.8 H...0.3 - 1.2.. ref SDS 30 KK9M
602590 - 17/11/2011 14:27 1.3 H.............. ref SDS 28 KK9M
602591 - 13/10/2011 14:35 1.3 H.............. ref SDS 27 GM65
602592 - 27/07/2011 12:58 2.0 H.............. ref SDS 23 GM65
602593 - 07/12/2010 09:17 1.0 ............... ref SDS 22 GM65
602594 - 21/07/2010 08:54 1.3 H.............. ref SDS 18 GM65
602595 - 14/12/2009 1.3 H ............. ref DRP 1 DE4O
602596 - 02/11/2009 0.9 ............... ref DRP 1 LG4L
602597 - 13/08/2009 15:09 1.7 H.............. ref SDS 12 VG8R
602599 - ..
602600 - This record indicates T Bili high 1.7, then dropped within range at
602601 - 0.9 after heart surgery (CABG+4) on 091022.
602603 - ..
602604 - On 131017 1000 VA Cardiology Progress Notes assessment report Doctor
602605 - Egan concerned about chronic hyperbilirubinemia. ref SDS 59 PSXT
602607 - ..
602608 - Today, Doctor Alba explained this record of T Bili 2.5 over 100% above
602609 - range represents mild elevation. She advised that vigorous exercise
602610 - from hiking 300+ miles per month (see above, ref SDS 0 T64J), can
602611 - increase bilirubin levels, shown in patient history discussed during
602612 - the meeting today, per above. ref SDS 0 T64J
602614 - ..
602615 - We reviewed the record indicating that correlating elevated T Bili
602616 - with high level of physical activity for endurance training appears
602617 - conflicting with the record that peripheral neuropathy symptoms
602618 - associated with elevated T bilirubin always decline within .25 miles
602619 - or so on daily 11 mile hikes, see for example the report in case study
602620 - on 120101, for 140517. ref SDS 29 YW5F
602622 - ..
602623 - The doctor was pleased that other liver enzymes are within range.
602625 - ..
602626 - She plans to follow up on elevated bilirubin issue, but did not
602627 - elaborate.
602629 - ..
602630 - [...below on 140519 0800 VA Progress Notes confirm
602631 - understandings that patient history shows T Bili was once
602632 - elevated before starting statins; plans to follow up with
602633 - repeat lab to check liver enzymes. ref SDS 0 OW65
602635 - ..
602636 - Doctor Alba advised that side effects should not affect prescribed
602637 - care with Atorvastatin and Ezetimibe. She explained medical practice
602638 - encourages patients to tolerate inconvenient side effects of effective
602639 - treatment in order to continue benefits recovering from primary
602640 - maladies like cancer, diabetes, cardiovascular disease (CVD), etc.
602642 - ..
602643 - This conflicts with case study of Millie's care shown on 050422 1645.
602644 - ref SDS 2 OW6O On 050514, Millie stopped treatment due to side
602645 - effects of chemotherapy. ref SDS 5 RU9M On 050516, she notified
602646 - Kaiser that death would be better than continuing side effects of
602647 - capecitabine. ref SDS 6 AQ6G However, on 050520 Mil agreed to resume
602648 - treatment with reduced dose for capecitabine (Xeloda) to reduce side
602649 - effects, ref SDS 7 NT3I, because labs showed significant decline in CA
602650 - 15-3 cancer marker. ref SDS 7 GJ5M Kaiser then supplemented lab work,
602651 - with a CT test that showed her cancerous nodes had shrunk so
602652 - dramatically that the doctor advised the issue was nearly totally
602653 - resolved, reported on 050610 1545. ref SDS 8 B58M
602655 - ..
602656 - Standard of care at Kaiser testing with labs and radiology that proved
602657 - effective reducing the dose of treatment to lower side effects in
602658 - Millie's case might be applied in the current case at the VA.
602659 -
602660 -
602662 - ..
602663 - Feet Pain Metatarsalgia Podiatry Referral Regression Atherosclerosis
602664 - Podiatry Resolve Metatarsalgia Feet Pain Maintain Regression Atherosclerosis
602665 - Atherosclerosis Podiatry Resolve Metatarsalgia Feet Pain Side Effects Physical Activity
602666 -
602667 - Besides possibly increasing T Bilirubin above range that might be
602668 - causing or compounding side effects of peripheral neuropathy, noted by
602669 - Doctor Alba today, per above, ref SDS 0 U56J, endurance exercise for
602670 - regression of atherosclerosis causes other side effects that compound
602671 - degenerative arthritis in the left knee.
602673 - ..
602674 - In recent months feet have begun to hurt from reducing CVD risk
602675 - through treatment with endurance exercise hiking 300+ miles per month,
602676 - continuing physical activity prescribed on 140213. ref SDS 81 E34O
602677 - Glucosamine Chondroitin reduces joint pain from hiking this year about
602678 - 300 miles ahead of the 1st 4 months of last year, per above.
602679 - ref SDS 0 T64J
602681 - ..
602682 - Increasing metatarsalgia pain on balls of feet due to treatment with
602683 - extended hiking was reported to Doctor Egan during a meeting in
602684 - Cardiology a few weeks ago on 140430 0900. ref SDS 91 PU37, and citing
602685 - case study on 120101 0900. ref SDS 29 PS3F At that time on 140430,
602686 - Doctor Egan indicated physical activity should continue in order to
602687 - maintain benefits of lowering CVD risk. ref SDS 91 RI9N
602689 - ..
602690 - Today, Doctor Alba also feels treatment should continue in order to
602691 - maintain good results lowering CVD risks, as discussed above.
602692 - ref SDS 0 A58I
602693 -
602694 - [On 140520 0732 letter to VA Medical Center in San
602695 - Francisco cites discussion on sore feet side effects of
602696 - hiking to lower CVD risk. ref SDS 97 UT5M
602698 - ..
602699 - Since February have tried to resolve metatarsalgia side effects by
602700 - purchasing shoes with increased cushioning, and further ordered
602701 - resoling shoes to increase cushioning, since new shoe models seem to
602702 - have less cushioning, cited in a letter to Resole America last month
602703 - on 140408 1826. ref SDS 90 5L95
602705 - ..
602706 - Requested referral to Podiatry for care of metatarsalgia in order to
602707 - continue treatment hiking 300 miles per month that has yielded weight
602708 - loss, lower LDL-P and triglycerides, higher HDL and EPCs that increase
602709 - regression of atherosclerosis, thus lowering CVD risk.
602711 - ..
602712 - Doctor Alba said to remove shoes and socks.
602714 - ..
602715 - She examined both feet to assess side effects of physical activity
602716 - treating atherosclerosis toward making referral to Podiatry for
602717 - resolution of debilitating metatarsalgia side effects.
602718 -
602719 -
602721 - ..
602722 - CT Test Response Treatment Favorable Results Reduce Treatment Side Effects
602723 -
602724 - We considered standard of care to reduce side effects by testing for
602725 - response to treatment using coronary CTA with calcium score,
602726 - addressing Doctor Alba's question on why test response to treatment?
602727 - ref SDS 0 467K Favorable test results could support reducing
602728 - treatments that would in turn reduce onerous side effects of
602729 - medication, ref SDS 0 PC8K, and endurance exercise. ref SDS 0 CC8O
602731 - ..
602732 - This aligns with experience at Kaiser when Doctor Johnson reduced dose
602733 - of capecitabine chemotherapy to reduce side effects for Millie, after
602734 - testing showed that initial high dose reduced the level of detectable
602735 - cancer, reported on 050520 1045. ref SDS 7 NT3I
602737 - ..
602738 - Doctor Alba will discuss testing issue further with the VA team toward
602739 - assessing viability of reducing treatment to reduce side effects based
602740 - on evidence of improved cardiovascular health.
602741 -
602742 - [On 151019 0930 CCTA with calcium score performed;
602743 - meeting with doctor in Radiology Department reviewed
602744 - requirements for calcium score to evaluate response to
602745 - treatment recovering from atherosclorosis. ref SDS B5
602746 - GR4K At the end of the meeting, the doctor agreed to
602747 - perform calcium score for comprehensive CCTA test.
602748 - ref SDS B5 LQ5F However, analyst's report merely says
602749 - "All the bypass grafts are patent." ref SDS B5 JW8O
602751 - ..
602752 - [On 151019 0930 addendum received on 160113, and issued
602753 - by Doctor Priyanka Jha reports finding no evidence of
602754 - atherosclerosis plaque in active coronary circulatory
602755 - system, or words to that effect. ref SDS B5 QW5F
602756 -
602757 -
602758 -
602759 -
602760 -
602761 -
6028 -
SUBJECTS
Default Null Subject Account for Blank Record
6103 -
610401 - ..
610402 - Medical Chart Progress Notes Meeting 140519 VA SF Medical Center
610403 -
610404 - Follow up ref SDS 81 476K, ref SDS 70 476K.
610405 -
610406 - On 140612 VA file from CD with Progress Notes for meeting on 140519
610407 - were received through US mail from VA Medical Center in San Francisco
610408 - ROI Department for request filed on 140519. Progress Notes were
610409 - signed on 140602. ref SDS 0 QQ5K
610411 - ..
610412 - VA Progress Notes for meeting on 140519 are stored in...
610413 -
610424 - ..
610425 - Generally, these Progress Notes correct numerous errors in past
610426 - Progress Notes carried forward to notes for the last meeting on 140213
610427 - 0830, ref SDS 81 3Q3N; implements request in the letter to the VA a
610428 - week or so later on 140529 0942. ref SDS A0 QF6T
610430 - ..
610431 - 1. LOCAL TITLE: ENDOCRINE-METABOLISM CLINIC F/U (MED)
610432 - STANDARD TITLE: ENDOCRINOLOGY OUTPATITNE NOTE
610433 - DATE OF NOTE: MAY 19, 2014 @ 1300
610434 - ENTRY DATE: MAY 30, 2014 @191229
610436 - EXP COSIGNER:
610437 - URGENCY:
610438 - STATUS: COMPLETED
610444 - ..
610445 - CC: follow up for high cholesterol
610447 - ..
610448 - 2. HPI
610449 -
610450 - 1. 69 year old man with Past Medical history of CAD, s/p CABG
610451 - in 2009, Hyperlipidemia, achalasia, s/p lap heller myotomy
610452 - and fundoplication in 2009, here today for follow up for
610453 - hyperlipidemia. He was last seen in endocrine clinic
610454 - February 2014.
610456 - ..
610457 - 2. He is currently on Zetia 10 mg po daily and Atorvastatin 10
610458 - mg daily.
610460 - ..
610461 - 3. Since his last appointment he reports multiple side effects
610462 - that he thinks are related to Atorvastatin.
610463 -
610464 - 1. Report dizziness when lying down and turning head-now
610465 - improved.
610467 - ..
610468 - Report of "improved" dizziness side effects aligns with the letter
610469 - reporting dizziness subsided, and sent to the VA on 140518 2120.
610470 - ref SDS 96 DV50
610472 - ..
610473 - Progress Notes should cite authority for "patient reports" so there is
610474 - an audit trail in the record that supports patient status and care.
610476 - ..
610477 - VA Progress Notes meeting 140519 continue...
610478 -
610479 - 2. Increased urination, mostly at night.
610481 - ..
610482 - 3. Dry mouth at night.
610484 - ..
610485 - 4. Also c/o right foot discomfort that is usually last only a
610486 - couple of seconds, occurs while standing or at low speed
610487 - while hiking. He has had 2 episodes in the past couple of
610488 - weeks. Mr Welch thinks right foot discomfort is due to
610489 - neuropathy; similar to what he experienced in 2012 when he
610490 - was on Rosuvastatin.
610492 - ..
610493 - Good report generally aligns with letter to VA on 140518. Neuropathy
610494 - sensations in right foot "...last only a couple of seconds..." while
610495 - standing in line. However, when hiking this lasts about .25 miles at
610496 - current pace, which would be about 3+ minutes, and less time if pace
610497 - is increased. (see letter to VA on 140518. ref SDS 96 DV59)
610499 - ..
610500 - VA Progress Notes meeting 140519 continue...
610501 -
610502 - 4. In the past couple of months, he has increased his intake
610503 - of orange juice.
610505 - ..
610506 - This aligns with the letter to VA on 140515 2043, ref SDS 95 PQXS, and
610507 - with discussions during the meeting, shown above. ref SDS 0 4Z8I
610508 -
610509 - [On 141024 0900 Progress Notes do not mention orange
610510 - juice 750 ML per day added to diet that maintained HDL
610511 - while hiking declined. ref SDS B1 IO6J
610513 - ..
610514 - This section can be strengthened by citing quantity reported, and
610515 - correlations between orange juice quantity, 21% rise in HDL, and
610516 - clinical study results that found 21% rise in HDL reviewed on 131125
610517 - 0005. ref SDS 66 K34L
610519 - ..
610520 - VA Progress Notes meeting 140519 continue...
610521 -
610522 - 5. Also he continues with vigorous exercise- hikes in average
610523 - 11-20 miles per day a couple of times per week. Reports
610524 - weight on May 13th was 165 pounds. BMI 29.
610526 - ..
610527 - VA should report patient applied Plan prescribed for care during prior
610528 - meeting at the VA shown in Progress Notes on 140213 0830. ref SDS 81
610529 - E34O
610531 - ..
610532 - VA should cite authority for data.
610534 - ..
610535 - Hiking a "couple times per week" conflicts with the record - this past
610536 - year, hiking occurs every day of the week with 3 - 4 days off per
610537 - month, averaging 300 miles per month, shown in case study on
610538 - medication, diet, vitals and exercise in the record on 120101 0900.
610539 - ref SDS 29 7718 This data is presented in lab reports on 140514,
610540 - which was referenced with electronic links in a letter on 140515 2043.
610541 - ref SDS 95 YM82
610542 -
610543 - [On 140629 1921 follow up letter to VA on 140520, ordering
610544 - coronary CTA with calcium score, ref SDS 97 VQ48, to assess
610545 - reducing level of care hiking 11 miles per day in order to
610546 - reduce side effects, ref SDS A6 UZ64; further request
610547 - referral to Podiatry for consultation to relieve
610548 - metatarsalgia side effects of prescribed care. ref SDS A6
610549 - U14H
610551 - ..
610552 - Weight reported on 140513 was 163, see case study. ref SDS 29 ZU5G
610554 - ..
610555 - This data was submitted to the VA in a letter on 140515 2043.
610556 - ref SDS 95 YM82
610558 - ..
610559 - Hiking mileage is also shown to reconcile improved labs in the record
610560 - on 140514 0950. ref SDS 94 I17G
610562 - ..
610563 - VA Progress Notes meeting 140519 continue...
610564 -
610565 - 6. Most recent labs at Labcorp and VA system showed a LDL
610566 - 87-83 HDL 66-67.
610568 - ..
610569 - 7. Mr Welch also reports recent labs that showed elevated potassium,
610570 - as well as elevated total bilirubin. His cardiologist brought up
610571 - these issues. Since May 2013 Potassium has ranged between
610572 - 4. -5.6 and T Bil between 1.3-2.1 [normal direct bilirubin]. Mr
610573 - Welch is concerned that this could be secondary to Atorvastatin.
610574 - His cardiologist also considered that dehydration and vigorous
610575 - exercise could be the cause of hyperkalemia and mildly elevated
610576 - bilirubin. Of note, review of records shows a total bilirubin of
610577 - 3.0 in October 2009- prior to initiation of statins.
610579 - ..
610580 - Curious VA does not present addendum reporting results of chem lab
610581 - ordered by Doctor Alba to evaluate dehydration theory, and reported on
610582 - 140520 0732. ref SDS 97 KK9M
610584 - ..
610585 - Citing "total bilirubin of 3.0 in October 2009 is not helpful, since
610586 - there were many labs - actually everyday post CABG on 091022. The
610587 - record on CABG was received from the VA on 100928 0706. ref SDS 19
610588 - PG5M
610589 -
610590 - Collection DT T Bili Range Source
610591 - 02/09/2012 11:18 1.8 H...0.3 - 1.2.. ref SDS 30 KK9M
610592 - 11/17/2011 14:27 1.3 H.............. ref SDS 28 KK9M
610593 - 10/13/2011 14:35 1.3 H.............. ref SDS 27 GM65
610594 - 07/27/2011 12:58 2.0 H.............. ref SDS 23 GM65
610595 - 12/07/2010 09:17 1.0 ............... ref SDS 22 GM65
610596 - 07/21/2010 08:54 1.3 H.............. ref SDS 18 GM65
610597 - 08/13/2009 15:09 1.7 H.............. ref SDS 12 VG8R
610598 - 11/02/2009 0.9 ............... ref DRP 1 LG4L
610599 - 12/14/2009 1.3 H ............. ref DRP 1 DE4O
610601 - ..
610602 - Cannot find lab with bilirubin 3.0 nor VA lab in October 2009?
610604 - ..
610605 - VA Progress Notes meeting 140519 continue...
610606 -
610607 - 3. Pertinent history.
610608 -
610609 - 1. Patient was started on Simvastatin approximately 2-3 years
610610 - ago, LDL at that time was around 180's - reports that his
610611 - LDL dropped to 96 while on simvastatin, however he reports
610612 - he develop "left shoulder myopathy"- he described pain on
610613 - his left shoulder and inability to raise it above 90
610614 - degrees- No CPK on records.
610616 - ..
610617 - 2. He was then started on Rosuvastatin 10 mg po daily and report
610618 - that his LDL improved. Rosuvastatin was then increased to 20 mg
610619 - and he developed sexual dysfunction, dizziness, dry mouth and
610620 - right foot numbness.
610622 - ..
610623 - 3. As per cardiology notes in September 2012- Rosuvastatin was
610624 - decreased to 10mg po daily and dizziness improved, but he
610625 - continued to complain of right foot numbness.
610627 - ..
610628 - 4. He now has he has been off the Rosuvastatin since 12/2012,
610629 - and he continues to complain of right foot numbness, but he
610630 - reports less episodes of right sole numbness with decreased
610631 - intensity. Of note, he was seen by neurology February 2013
610632 - for the foot numbness, Vit B12 level was within normal
610633 - range, fasting glucose level ranges from 108 to 115 mg/dl,
610634 - Hga1c 5.5 October 2013; as per neurology notes no evidence
610635 - of radiculopathy or neuropathy.
610637 - ..
610638 - 4. Past Medical, Surgical, social and family history reviewed an
610639 - unchanged
610641 - ..
610642 - This note reflects entry in Progress Notes para 4, PSH, for meeting at
610643 - VA on 131121 0930. ref SDS 64 W49F
610645 - ..
610646 - Patient Medical History is shown in Progress Notes for meeting with
610647 - Doctor Egan in Cardiology on 140430 0900. ref SDS 91 TX50
610649 - ..
610650 - VA Progress Notes meeting 140519 continue...
610651 -
610652 - 5. ROS- see above
610654 - ..
610655 - 6. MEDICATIONS:
610656 - Omeprazole 20 mg BID
610657 - Atorvastatin 10 mg po daily
610658 - Zetia 10 mg po daily
610660 - ..
610661 - 7. PHYSICAL EXAM
610662 - VS
610663 - HT: 66 in [167.6 cm] (12/16/2009 18:00)
610664 - WT: 187.2 lb [85.1 kg] (05/19/2014 08:07)
610665 - HR: 61 (05/19/2014 08:07)
610666 - BP: 115/68 (05/19/2014 08:07)
610667 - Temp: 97.1 F [36.2 C] (12/20/2009 08:46)
610668 - RR: 18 (02/13/2014 08:19)
610669 - O2 Sat: 5/19/14 08:07:12 O297
610670 - BMI: 30.3 (Obesity Level I)
610672 - ..
610673 - 8. PE
610674 - Gen : NAD, AAO x3
610675 - HEENT : NC/AT, MMM, PERRL.
610676 - Neck : supple.
610677 - CARDIO : RRR, no murmurs appreciated
610678 - LUNGS : CTA Bl, no wheezes, no rales
610679 - EXT : no edema, no cyanosis, no xanthemas.Normal sensations. +
610680 - onychomychosis in bilateral feet. Normal sensation.
610682 - ..
610683 - 9. LABS:
610684 - May 14 2014
610685 - 05/14/2014 CHOLESTEROL 164.00 100 - 240 PLASMA
610686 - 05/14/2014 TRIGLYCERIDE 58.00 10 - 190 PLASMA
610687 - 05/14/2014 HDL 66.00 35 - PLASMA
610688 - 05/14/2014 LDL CHOL(Calculated 87.00 - 131 PLASMA
610689 - 05/14/2014 HEMOGLOBIN A1C 5.40 4.0 - 6.0 SERUM
610691 - ..
610692 - 10. PLASMA ALB TP
610693 - [c] May 14, 2014 10:16 4.6 7.5
610695 - ..
610696 - 11. PLASMA ALKP SGOT SGPT
610697 - [c] May 14, 2014 10:16 93 33 27
610698 -
610699 - 12. ********************************************************
610701 - ..
610702 - 13. PLASMA T BIL D BIL
610703 - [c] May 14, 2014 10:16 2.2 H 0.2
610705 - ..
610706 - 14. VA System
610707 - May 8 2014 TC 162 LDL 83 HDL 67 TG 59
610708 - Feb 3rd 2014 TC 160 LDL 93 HDL 58 TG 47 HgA1c 5.5%
610709 - Labcorp TC 156 LDL 81 HDL 61 TG 61
610711 - ..
610712 - 15. October 2013 TC 321 LDL 249 HLD 50 TG 85 TBil 1.7
610713 - Hga1c 5.5% CPK 110 TSH 2.6
610715 - ..
610716 - 16. May 2013 TC 307 LDL 240 HLD 54 TG 85 TBil 1.3
610717 - November 2012 TC 173 LDL 105 HLD 57 TG 53 TBil 1.6
610718 -
610720 - ..
610721 - 17. Assessment and Plan:
610722 -
610723 - 18. 69 year old male with history of CAD, s/p CABG in 2009,
610724 - Hyperlipidemia, referred by cardiology for management of
610725 - hyperlipidemia. Here today for follow up.
610727 - ..
610728 - 19. Again improved LDL on Atorvastatin 10 mg po daily and Zetia 10 mg
610729 - daily, although still not at goal on a patient with known
610730 - coronary artery disease and CABG. LDL goal is less than 70mg/dL.
610731 - Explained to Mr Welch that although diet and exercise are
610732 - important lifestyle changes in the management of hyperlipidemia,
610733 - he needs to continue current regimen to achieve LDL goal.
610735 - ..
610736 - VA Progress Notes saying "...LDL is still not at goal," appears
610737 - conflicting with VA lab on 140514, finding LDL-C 87, and Labcorp blood
610738 - test on 140508, shows LDL-C 83, well below VA published "goal" <= 130,
610739 - and Labcorp "goal" < 100, all shown in consolidated results on 140514
610740 - 0950. ref SDS 94 W25L Recent guidance published by American Heart
610741 - Association - AHA - shows LDL-C "goal" < 190, reported on 131112 1422.
610742 - ref SDS 61 HT87
610743 -
610744 - [On 141106 0630 make-up lipid blood test reported LDL-C 67,
610745 - which aligns with VA "goal" for LDL-C < 70, ref SDS B4
610746 - U45J; however, it results from 20 unit deline in total
610747 - cholesterol from 156 to 137 over just 2 weeks, and so
610748 - conflicts with patient history of stable cholesterol for
610749 - prior 12 months. ref SDS B4 W25L
610751 - ..
610752 - VA should submit authority for LDL goal < 70 - presenting medical
610753 - analysis, study, etc., that justifies "goal" of LDL-C < 70?
610755 - ..
610756 - Since LDL-P 851 was reported on Labcorp NMR test 140508, and since
610757 - Labcorp guidance says LDL-P <1000 is the best lipid condition for
610758 - cardio vascular health shown in consolidated labs on 140514 0950,
610759 - ref SDS 94 BE6O, and since VA Progress Notes say LDL-P has stronger
610760 - association with CVD risk than LDL-C, reported on 131219 0930,
610761 - ref SDS 70 GO35, then why are LDL-P results not reported in Progress
610762 - Notes showing alignment with "goal" to lower CVD risk?
610764 - ..
610765 - VA Progress Notes meeting 140519 continue...
610766 -
610767 - 20. Mr Welch inquired about medical trials for PCSK9 ab. At this
610768 - time, there are no clinical trials at SF VA involving PCSK9.
610769 - Patient was provided with information regarding clinical trials
610770 - in the bay area, in December 2013.
610772 - ..
610773 - 21. Mr Welch also expressed interest in CTA to assess regression of
610774 - atherosclerotic plaques. Dr Feingold explained to Mr welch that
610775 - CTA is not used in patients that have already had CABG, since the
610776 - anatomy has changed, and in his case we know that the many of his
610777 - coronaries have plaques and calcifications- that being the reason
610778 - he needed to undergo coronary artery bypass grafting in 2009.
610780 - ..
610781 - This aligns with discussion during the meeting this morning, where
610782 - Doctor Feingold intertwined his fingers to illustrate tangled changes
610783 - to anatomy from CABG surgery, which he maintained prevented analysing
610784 - atherosclerotic plaques in coronary blood vessels, per above.
610785 - ref SDS 0 J83H For some reason, Progress Notes omit research showing
610786 - coronary CTA with calcium score is standard of care to test response
610787 - to treatment for regression of atherosclerosis, per above. ref SDS 0
610788 - OF7N
610790 - ..
610791 - [On 151019 0930 CCTA with calcium score performed;
610792 - meeting with doctor in Radiology Department reviewed
610793 - requirements for calcium score to evaluate response to
610794 - treatment recovering from atherosclorosis. ref SDS B5
610795 - GR4K At the end of the meeting, the doctor agreed to
610796 - perform calcium score for comprehensive CCTA test.
610797 - ref SDS B5 LQ5F However, analyst's report merely says
610798 - "All the bypass grafts are patent." ref SDS B5 JW8O
610800 - ..
610801 - [On 151019 0930 addendum received on 160113, and issued
610802 - by Doctor Priyanka Jha reports finding no evidence of
610803 - atherosclerosis plaque in active coronary circulatory
610804 - system, or words to that effect. ref SDS B5 QW5F
610806 - ..
610807 - During the meeting today, Doctor Alba and Doctor Feingold further
610808 - maintained that coronary CTA with calcium score is not standard of
610809 - care to test for regression of atherosclerosis because knowing the
610810 - severity of atherosclerosis plaques will not add any value to current
610811 - diagnoses or treatment, per above. ref SDS 0 M16K
610813 - ..
610814 - Controversy using CCTA radiology studies in clinical cardiology
610815 - practice to assess atherosclerosis was cited in discussions at an
610816 - international conference considering prospects for HDL to regress
610817 - plaque, reported last year On 131125. ref SDS 66 1E51
610818 -
610819 - [On 141009 0900 ad hoc discussion - doctor in VA Cardiology
610820 - Department used very similar language to discourage
610821 - customers seeking coronary CTA with calcium score to test
610822 - for response to treatment recovering from atherosclerosis
610823 - and for the purpose of lowering risk of CVD. ref SDS A9
610824 - AK6K
610826 - ..
610827 - These Progress Notes do not present discussions during the meeting
610828 - that testing to disclose severe atherosclerosis provides opportunity
610829 - to adjust treatment in time to be effective, citing well known case of
610830 - Tim Russert. ref SDS 0 6W3M The notes do not set out representations
610831 - to the effect that alternative treatments are not available at the VA,
610832 - nor that patients are entitled to the opportunity to seek alternative
610833 - treatment, if needed, including clinical trials with PCSK9 drugs, per
610834 - above. ref SDS 0 6P4I
610836 - ..
610837 - Progress Notes further omit discussion of opportunity to reduce
610838 - treatment in order to reduce both cost and severe side effects in the
610839 - event testing finds significant regression of atherosclerosis, per
610840 - above. ref SDS 0 635O
610841 -
610842 - [On 140529 0942 letter to VA requests progress ordering EPC
610843 - lab, and requests order for coronary CTA with calcium score
610844 - standard of care to test for response to treatment to
610845 - achieve regression of atherosclerosis. ref SDS A1 QG38
610847 - ..
610848 - [On 140612 1048 letter from Doctor Alba says VA refuses to
610849 - order EPC and CTA tests to evaluate regression of
610850 - atherosclerosis because CABG surgery on 091022, changed
610851 - anatomy which renders CTA test difficult, and since
610852 - customer has history of atherosclerosis the VA will test to
610853 - evaluate whether the problem has been resolved, declined,
610854 - unchanged or worsened, ref SDS A2 X45G, reflecting remarks
610855 - by Doctor Feingold as presented in Progress Notes for
610856 - meeting at VA on 140519 0800. ref SDS 0 OW49
610858 - ..
610859 - [On 140626 1652 letter notifies VA of case studies showing
610860 - failure to perform timely testing causes negative patient
610861 - outcomes. ref SDS A4 MY51 VA reference to patient having
610862 - vessel plaques 5 years ago, begs the question of testing to
610863 - determine currently how much plaque, and level of care
610864 - required, if any, to treat current condition. ref SDS A4
610865 - MZ33 Evidence shows CTA common procedure to evaluate
610866 - current condition post CABG surgery. ref SDS A4 MZ54
610868 - ..
610869 - VA Progress Notes meeting 140519 continue...
610870 -
610871 - 22. Regarding elevated potassium, this could be secondary to vigorous
610872 - exercise, since potassium can be released from active muscle
610873 - cells. No reports of statin causing hyperkalemia. Will plan to
610874 - repeat potassium levels. Instructed Mr Welch to repeat labs on a
610875 - day that he is appropriately hydrated and avoid hiking the day
610876 - prior to lab tests.
610878 - ..
610879 - 23. Review of records showed elevated total bilirubin [ with normal
610880 - direct bilirubin levels] since 2009- prior to initiation of
610881 - statins. Most likely mild elevation of unconjugated bilirubin is
610882 - secondary to Gilbert's syndrome. Gilberts' syndrome is a
610883 - phenotypic defect that causes increase in unconjugated bilirubin
610884 - under conditions of exertion, stress, fasting or infection and is
610885 - usually asymptomatic. Also vigorous exercise can increase
610886 - bilirubin levels due to destruction of red blood cells. All
610887 - other liver enzymes are within normal limits. Will follow up.
610889 - ..
610890 - This analysis aligns with understandings during the meeting with
610891 - Doctor Alba finding patient history shows 1 slightly elevated
610892 - potassium lab in 2009 prior to CABG, which then declined, but
610893 - increased markedly over next few years with prescription of statins
610894 - and increased dosage, possibly reflecting progressive injury to liver.
610895 - per above. ref SDS 0 UI3F
610897 - ..
610898 - VA Progress Notes meeting 140519 continue...
610899 -
610900 - 24. Plan
610901 -
610902 - 1. Continue Atorvastatin 10 mg po daily and Zetia 10 mg po daily.
610903 -
610904 - 2. Weight reduction- Current BMI of 29. Encourage low fat/low
610905 - carbohydrate diet.
610907 - ..
610908 - Progress Notes for prior meeting on 140213 presented a Plan - "Weight
610909 - stable, continue physical activity and low fat/low cholesterol diet."
610910 - ref SDS 81 E34O During the meeting today, the doctor credited
610911 - effective implementation of the prior plan for physical activity, per
610912 - above, ref SDS 0 K77I, based on hiking 300+ miles per month, also
610913 - above. ref SDS 0 T64J Doctor citing elevated BMI of 29, appears
610914 - conflicting with Progress Notes work plan today failing to continue
610915 - prior prescription for physical activity that yields weight loss,
610916 - favorable lipid profile, and regression of atherosclerosis that
610917 - reduces CVD risk.
610919 - ..
610920 - VA Progress Notes meeting 140519 continue...
610921 -
610922 - 3. Follow up Lipid panel in 4 months prior to next appointment.
610923 -
610924 - 4. Will repeat potassium and liver enzymes levels in 1 weeks.
610926 - ..
610927 - 25. Patient was seen and discussed with Dr Feingold
610929 - ..
610930 - 26. Clinical Reminder Activity
610932 - ..
610933 - 27. MED REC NON PRIMARY CARE:
610935 - ..
610936 - 28. Medication Reconciliation completed, including non-VA
610937 - medications and discrepancies, if identified, were
610938 - addressed.
610940 - ..
610941 - 29. Medication, medication changes and importance of medication
610942 - management were reviewed with the patient/caregiver. An
610943 - updated list of reconciled medications has been provided to
610944 - the patient/caregiver.
610946 - ..
610947 - 30. /es/ DIANA ALBA, MD
610948 - Endocrinology Fellow
610949 - Signed: 06/02/2014 07:20
610950 -
610951 -
610952 -
610953 -
610954 -
610955 -
610956 -
610957 -
610958 -
610959 -
610960 -
610961 -
610962 -
610963 -
610964 -
610965 -
610966 -
610967 -
610968 -
610969 -
610970 -
610971 -
610972 -
6110 -